aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept
Go back to aTyr Pharma expects FDA response on Phase 3 sarcoidosis trial by mid-Sept| (NASDAQ: ATYR) | Delayed: 0.36 -0.02 (5.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.38 | 52 Week High | $ | |||
| Open | $0.37 | 52 Week Low | $ | |||
| Day High | $0.39 | P/E | N/A | |||
| Day Low | $0.36 | EPS | $ | |||
| Volume | 1,259,441 | |||||
